BRAF and ZNF189

Number of citations of the paper that reports this interaction (PubMedID 24412244)
2

Data Source:
BioGRID (two hybrid)

		BRAF	ZNF189
Description		B-Raf proto-oncogene, serine/threonine kinase	zinc finger protein 189
Image			No pdb structure
GO Annotations	Cellular Component	Nucleus Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle	Nucleus
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Activity MAP Kinase Kinase Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding Scaffold Protein Binding Protein Serine Kinase Activity	RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific Metal Ion Binding
	Biological Process	MAPK Cascade Protein Phosphorylation Epidermal Growth Factor Receptor Signaling Pathway Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane	Regulation Of Transcription By RNA Polymerase II
Pathways		Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Generic Transcription Pathway
Drugs		Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib
Diseases
GWAS		Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Longevity ( 33657282) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 32499647 28869590)
Interacting Genes		45 interacting genes: AKT1 ARAF AURKA BAD CCDC88A CTSV FBP1 HRAS HSD17B3 ICAM1 ITCH LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MAPK3 MRAS NANOG OIP5 PAK2 PEBP1 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT YWHAB YWHAG YWHAH YWHAQ YWHAZ ZNF189 ZNF510	15 interacting genes: AURKA AXIN2 BMPR1A BRAF BUB1 CTNNA1 CYP1A1 DLC1 ERBB2 KRAS MCC PMS2 SMAD4 SRC STK11
Entrez ID		673	7743
HPRD ID		01264	11930
Ensembl ID		ENSG00000157764	ENSG00000136870
Uniprot IDs		P15056	A0A087X0K2 B7ZLK9 O75820
PDB IDs		1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6P3D 6P7G 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN 6UUO 6V2U 6V2V 6V2W 6V2X 6V2Y 6V2Z 6V30 6V31 6V32 6XAG
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?